Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2018, Article ID 3476476, 10 pages
https://doi.org/10.1155/2018/3476476
Research Article

In Vivo MRI of Functionalized Iron Oxide Nanoparticles for Brain Inflammation

1Chemistry Graduate Group, University of California, Davis, CA 95616, USA
2Department of Neurology, School of Medicine, University of California Davis, 4860 Y Street, Sacramento, CA 95817, USA
3Centre National de la Recherche Scientifique (CNRS), Neurodegenerative Diseases Laboratory, Université Paris-Sud, Université Paris-Saclay, UMR 9199, 92260 Fontenay-aux-Roses, France
4Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Direction de la Recherche Fondamentale (DRF), Molecular Imaging Research Center (MIRCen), 92260 Fontenay-aux-Roses, France
5Department of Biomedical Engineering, University of California, Davis, CA 95616, USA

Correspondence should be addressed to Angelique Y. Louie; ude.sivadcu@eiuolya and Marc Dhenain; rf.aec@nianehD.craM

Received 26 February 2018; Revised 3 May 2018; Accepted 9 May 2018; Published 25 June 2018

Academic Editor: Anne Roivainen

Copyright © 2018 Tang Tang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Microglia are intrinsic components of the brain immune system and are activated in many central nervous system disorders. The ability to noninvasively image these cells would provide valuable information for both research and clinical applications. Today, most imaging probes for activated microglia are mainly designed for positron emission tomography (PET) and target translocator proteins that also reside on other cerebral cells. The PET images obtained are not specific for microglia-driven inflammation. Here, we describe a potential PET/MRI multimodal imaging probe that selectively targets the scavenger receptor class A (SR-A) expressed on activated microglia. These sulfated dextran-coated iron oxide (SDIO) nanoparticles are avidly taken up by microglia and appear to be nontoxic when administered intravenously in a mouse model. Intravenous administration of this SDIO demonstrated visualization by -weighted MRI of microglia activated by intracerebral administration of tumor necrosis factor alpha (TNF-α). The contrast was significantly enhanced by SDIO, whereas there was little to no contrast change in animals treated with nontargeted nanoparticles or untreated controls. Thus, SR-A targeting represents a promising strategy to image activated microglia in the brain.

1. Introduction

Inflammation occurs in various central nervous system diseases, such as neurodegenerative diseases, epileptic disorders, as well as autoimmune diseases. Microglia, the resident macrophages in the brain, are recognized as the prime components of an intrinsic brain immune system and are the key cellular mediators of neuroinflammatory processes [1]. The activation of microglia can be triggered by an assortment of inflammatory stimuli to the central nervous system (CNS) that includes stroke, seizures, Alzheimer’s disease (AD), traumatic brain injury, and CNS storage diseases [26]. Activated microglia are capable of synthesizing a broad range of proinflammatory and anti-inflammatory cytokines and other molecular mediators [7] that can lead to changes in the permeability of the blood-brain barrier followed by infiltration of peripheral immune cells into the CNS, increased secretion of inflammatory cytokines, exacerbated tissue damage, and neuron loss [8]. Thus, noninvasive methods for identifying activated microglia in vivo could lead to earlier detection of neuroinflammation and provide a means for monitoring disease progression and therapeutic intervention.

Earlier efforts have reported the development of in vivo, neuroinflammatory PET diagnostic agents targeting activated microglia through the peripheral benzodiazepine receptor (PBR), now known as the 18 kDa translocator protein (TSPO). 11C-PK11195 is one of the most widely used ligands for PET imaging of microglia in patients with neurological disorders, but this first-generation TSPO radiotracer demonstrates poor signal-to-noise ratio and poor selectivity [9, 10]. Newer tracers, such as 11C-PBR28, with improved TSPO binding or selectivity have been introduced and initiated in clinical studies [1113]. Unfortunately, TSPO genetic polymorphism can adversely affect the binding of 11C-PBR28 leading to signal variability [14, 15]. The density of TSPO in the brain is very low, even in a neurodegenerative setting [16], and the presence of TSPO on other brain cell types reduces the specificity of TSPO [17] and its PET signal coregistered with both activated microglial cells and reactive astrocytes following LPS induced inflammation [10]. A more selective biomarker for activated microglia that could be visualized by PET or high-resolution MRI would be of therapeutic value.

Instead of using TSPO as a target, we labeled activated microglia through the scavenger receptors class A (SR-A). SR-A type scavenger receptors have been shown to be upregulated on activated microglia in pathological states and not present on quiescent adult microglia [18]. SR-A initiates inflammatory responses by recognizing pathogen- or damage-associated molecular patterns (DAMPs) [19]. SR-A expression is associated with the activation/polarization of the microglia. Because of their role in inflammation, SR-A receptors are not downregulated with ligand concentration. They also mediate very efficient and rapid internalization of bound ligand [20] and repeatedly recycle through the endosomal compartment, illustrating desirable traits as targets for labeling [2124].

Previously, our group has developed iron oxide-based PET/MRI probes that are targeted to activated macrophages through the SR-A type scavenger receptors to image vulnerable atherosclerotic plaques [2527]. Given the presence of this same receptor on activated microglia, in this work we investigate an improved imaging probe and demonstrate the ability to specifically label and image activated microglia in a mouse model of brain inflammation [28]. The probe is sulfated dextran-coated iron oxide (SDIO) nanoparticles conjugated with the macrocyclic chelator 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (DO3A); the surface sulfation allows for specific targeting to SR-A. Sulfated dextran (a.k.a. dextran sulfate) is widely known as one of the ligands for SR-A with a Kd of 3 nM [29]. In our previous study, we have confirmed that the sulfation of dextran coating significantly improved the cellular binding and uptake of these nanoparticles by macrophages and the uptake efficiency enhances with higher level of surface sulfation [30]. The sulfated dextran-coated iron oxide nanoparticles have a similar binding affinity to the SR-A, compared with dextran sulfate itself. Thus, we hypothesize that these particles will also serve as promising imaging probes to visualize activated microglia in vivo. From the series of nanoparticles that we reported in previous work, SDIO-DO3A-10 had the highest surface sulfation level and best uptake efficiency [30]. SDIO-DO3A-10 and the nonsulfated analog DIO-DO3A are used in this study and referred to as SDIO and DIO, respectively. Here, we demonstrate the specific targeting of SDIO to activated microglia in vitro and their efficient MRI contrast enhancement ability in a mouse model of brain inflammation as a first step in validation for microglia imaging.

2. Materials and Methods

2.1. General Materials

Materials were purchased from commercial suppliers and used directly, unless specifically noted. Human TNF-α was purchased from PeproTech Inc. (Rocky Hill, NJ). Sulfated dextran-coated iron oxide was synthesized as described in our previous paper [30]. Lipopolysaccharides were purchased from Sigma-Aldrich (St. Louis, MO). Fetal bovine serum (FBS), L-glutamine, and Dulbecco’s phosphate-buffered saline (DPBS) (1x) were from GIBCO. Lipoprotein-deficient bovine serum (LPDS) was obtained from Biomedical Technologies, Inc. (Stoughton, MA). Murine BV2 microglia were obtained from American Type Culture Collection (ATCC). Saline and isoflurane were acquired from APP Pharmaceuticals, LLC (Schaumburg, IL), and Piramal Healthcare Limited, respectively. Buprenex Injectable was received from Reckitt Benckiser Healthcare Ltd. Beuthanasia-D Special was purchased from Schering-Plough Animal Health Corp.

2.2. Syntheses of DIO and SDIO

Nanoparticles were synthesized and characterized as previously described in detail [30]. Briefly, dextran-coated iron oxide (DIO) nanoparticles were synthesized by coprecipitation of iron salts and reduced dextran with the addition of ammonium hydroxide. Purified DIO was conjugated with the DO3A chelator, which has high stability for copper-64 ions. This generated multimodal function for either PET or MRI applications. Conjugation of the chelator is a two-step reaction directly coupling to the hydroxyl groups in the dextran coating, and we sulfated the dextran coating after conjugation of the chelator to maximize the sulfate level on the surface. The highest sulfation level was used to synthesize SDIO nanoparticles. Extensive physical characterizations such as dynamic light scattering for hydrodynamic size distribution, transmission electron microscopy (TEM) for iron oxide core size, atomic absorption spectroscopy (AAS) for iron content percentage, combustion infrared for sulfur content percentage, and relaxivity measurements were performed on both nonsulfated precursor DIO and SDIO nanoparticles.

2.3. Biocompatibility

Biocompatibility of SDIO on murine BV2 microglia was evaluated using C12-resazurin viability assays. BV2 cells were maintained in Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS) and penicillin-streptomycin (100 U/mL) at 37°C in a humidified 5% CO2 atmosphere. To perform the viability experiments, BV2 cells were plated in 96-well plates at a concentration of 104 cells per well and incubated in a 5% CO2 atmosphere at 37°C overnight. The medium was then replaced with fresh media containing varying concentrations of SDIO (at 0.04, 0.2, 1, 4, 10 mM [Fe]) and incubated for 4 or 24 h. The medium was then removed, and the cells were washed with Dulbecco’s phosphate-buffered saline solution (DPBS) three times. Media containing C12-resazurin (5 μM) was then added to the wells, and after a 15 min incubation, fluorescence was measured on a Safire2 monochromator microplate reader (Tecan Austria, Groedig, Austria) with excitation at 563 nm and emission at 587 nm.

2.4. Cellular Uptake Studies

To study the specific cellular uptake of SDIO nanoparticles by microglia, BV2 cells (between passages 20 and 40) were grown/maintained in Dulbecco’s Eagle’s minimum essential medium (DMEM) containing 10% fetal bovine serum (FBS) and penicillin-streptomycin (100 U/mL) in 5% CO2 and then plated in 6-well plates at a concentration of 1 × 106 cell/well (2 mL). After reaching ∼80% confluency, plated cells were rinsed twice with Dulbecco’s phosphate-buffered saline solution (DPBS) and activated through exposure to lipopolysaccharide (LPS) in serum-free media at a final concentration of 200 ng/well for 6 h. Activated BV2 cells were incubated with DIO or SDIO solutions at different concentrations (25, 50, and 100 μM iron) for 1 h. Plated cells were then rinsed three times with DPBS. Deionized water (1 mL) was then added, and the freeze/thaw (30 min/20 min) method was repeated twice to lyse cells. Cell lysates were lyophilized, and DI water (0.3 mL) was added to the residue to prepare the solution for T2 measurement by the Bruker Minispec mq60. T2 values were measured using a Carr–Purcell–Meiboom–Gill sequence, with τ = 1 ms and 200 data points.

2.5. In Vivo Study

All animal experiments were performed under a protocol approved by the UC Davis Institutional Animal Care and Use Committee (UCD Institutional # 18025). BALB/c mice (18–22 g, 9 weeks old) were obtained from Charles River Laboratories, Wilmington, MA. SDIO and DIO were evaluated after intravenous (IV) administration in mouse models of cerebral inflammation and in control animals. Brain inflammation was induced by unilateral intracerebral injection of human TNF-α according to a protocol previously reported in the literature [28]. Four experimental groups were evaluated: (1) TNF-α only (), (2) TNF-α + IV-SDIO (), (3) TNF-α + IV-DIO (), and (4) IV-SDIO only (). Mice in group 1 received intracerebral inoculation of TNF-α to assess whether the chemically induced inflammation in the brain produced endogenous contrast changes. The ability of intravenous SDIO or DIO to enhance contrast on MR images of inflamed brains was tested in the groups 2 and 3. Group 4 was designed to evaluate the impact of SDIO on the normal brain. The timeline of this study is shown in Figure 1.

Figure 1: Overview of the in vivo study timeline.

The unilateral intracerebral injection protocol consisted of isoflurane anesthesia (1–5% inhalation route, typically at 3% induction, 1.5–2% maintenance) of animals and placement into a stereotactic device maintained at 37 ± 0.2°C on a feedback-controlled heating pad. The scalp was shaved and prepared using 3 cycles of betadine and isopropyl alcohol prior to any incisions. A small burr hole was drilled on the left side into the skull of the mice, and TNF-α (1 μg in 1 μL) was injected (at coordinate 0.5 mm anterior, 2.0 mm lateral, and −3 mm ventral to the bregma) through a 26-gauge needle within a period of 3 minutes [28]. The opening was sutured using an Ethilon nylon suture with 18″ and P-3 reverse cutting. Buprenex (0.1 mg/kg) was administered subcutaneously at the end of the procedure and then 2 times daily for 48 h. The animals were monitored regularly for pain or discomfort.

Four milligrams of SDIO was dissolved in 150 µL of injectable saline in a 1.5 mL Eppendorf vial and vortexed for 5 seconds to obtain a uniform solution. The solution was then passed through a 0.2-micron filter for sterilization and ready for injection. Animals were anesthetized under isoflurane, and SDIO was administered intravenously via tail vein with up to 150 μL, 20 mg/kg of Fe, 24 h after intracerebral injection of TNF-α. Control animals were injected with the untargeted probe, DIO, of comparable composition to the experimental probe being tested. The injected dose was adjusted to match the same iron content as 20 mg/kg of animal.

2.6. MRI and Signal Processing

All images were acquired from a 7-Tesla (300 MHz) Bruker Avance Biospec system (Billerica, MA) equipped with a 95 mT/m max gradient set and 35 mm ID Doty coil, at ambient temperature (25°C). Anesthesia (isoflurane, inhalation, 1–3%) was administered during imaging acquisition. The animals were imaged 22 h after intracerebral injection of TNF-α and imaged again 4, 24, and 48 h after imaging probe injection (illustrated in Figure 1). A water heating pad was used on the animal holder and maintained at 37°C to prevent hypothermia. Each animal was imaged by -weighted sequences (FLASH 2D) with TR = 500 ms, TE = 5 ms, angle = 24°, NA = 8, FOV = 20 × 20 mm2, matrix = 128 × 128, slice thickness = 0.67 mm, and 12 slices.

Signal intensity and background noise for each 0.67 mm -weighted image slice was determined using Image J/Fiji software [31]. To compare particle uptake between time points and subjects, we calculated the contrast-to-noise ratio (CNR) generated by the probes on -weighted images. CNR was calculated as the difference in signal intensity between the injured site and the control region in the contralateral side of the brain scaled to image background noise. ROIs were drawn manually at the level of the injured site and were similar between all imaging time points.

2.7. Histology Analysis

Immediately following the final imaging time point at 48 h, the animals were anesthetized by high dose of anesthesia solution (Euthasol, 100 mg/kg, i.p.) followed by transcardial perfusion with phosphate-buffered saline (0.9%) and 10% buffered formalin phosphate solution. Brain tissue was dissected and postfixed in 10% buffered formalin phosphate solution at 4°C. Then, they were cryoprotected by incubation overnight in sucrose 30% solution. Forty-micrometer-thick coronal brain sections were cut on a freezing microtome (SM2400; Leica Microsystem, Wetzlar, Germany), and free-floating serial sections were preserved in a storing solution (glycerol 30%, ethylene glycol 30%, distilled water 30%, and PBS 10%) at −20°C until use.

Each brain was then processed for a double staining for microglia (anti-Iba-1 antibody) and iron (Perls’ Prussian blue staining). Free-floating sections were rinsed in PBS 0.1 M and incubated with hydrogen peroxide 0.3% for 20 minutes. Pretreatment in a blocking solution for 30 minutes (PBS-Triton X-100, 0.2% (Sigma-Aldrich, MO, USA) and 4.5% normal goat serum) was performed before a 48-hour incubation, at +4°C, with the anti-Iba-1 antibody (Wako-019-19741, 1/1000 (Neuss, Germany)). Then, sections were incubated for 1 hour in secondary biotinylated anti-rabbit antibody (Vector Laboratories, 1/1000, Burlingame, CA, USA) before revelation. ABC Vectastain kit (Vector Laboratories, 1/250, Burlingame, CA, USA) was used for DAB revelation (DAB SK4100 kit, Vector Laboratories, Burlingame, CA, USA). The floating sections were then mounted on slides before Perls’ staining, performed the next day. For Perls’ staining, the slides were incubated in a methanol 20% and hydrogen peroxide 3% solution for 10 minutes. They were rinsed with distilled water and PBS 0.1 M before to be incubated with 2% potassium ferrocyanide (P9387, Sigma-Aldrich) and 2% hydrogen chloride solution for 20 minutes. The sections were finally dehydrated, covered by a cover slip, and digitized with a Zeiss AxioScan.Z1 (Oberkochen, Germany) whole-slide imaging microscope at a lateral resolution of 0.5 μm.

2.8. Statistical Analysis

Unpaired two-tailed t-test was used to compare the means between different groups. A t statistic is calculated with t = difference in sample means/SE of difference in sample means. A value is obtained by comparison with the t distribution on degrees of freedom. was then considered significant. Nonparametric Mann–Whitney U test was also performed for the in vivo study () to compare with the parametric t-test.

3. Results

3.1. Syntheses and Characterization of DIO and SDIO

The synthesis and physical characterization of both DIO and SDIO were reported in a previous article [30]. The properties of the materials synthesized for the current studies were confirmed to match to our published results. A schematic representation of SDIO is shown in Figure 2; DIO is the nonsulfated analog. Both types of nanoparticles had an iron oxide core size of 6 nm. The average hydrodynamic diameter of DIO and SDIO was around 20 and 60 nm, respectively. The increased size of SDIO was likely due to the repulsion between the negatively charged sulfate groups on the surface, which made the dextran coat expand. The iron content by total mass was 20% in DIO and 10% in SDIO. The zeta potential of the sulfated nanoparticles was −45 mV, while DIO had a positive charge of +11.7 mV in deionized water. Both nanoprobes had high relaxivities (DIO: r1 = 17.9 mM−1·s−1, r2 = 103.3 mM−1·s−1; SDIO: r1 = 14.2 mM−1·s−1, r2 = 72.8 mM−1·s−1), and the high r2/r1 ratios are indicative of good negative contrast agents. The decrease in relaxivity after sulfation could be due to the thicker coating of SDIO nanoparticles, which increases distance of the core from surrounding water, could reduce water exchange through the polysaccharide layer, and modulate relaxivity.

Figure 2: Schematic representation of SDIO.
3.2. SDIO Is Biocompatible to Microglia

In our previous work, SDIO nanoparticles were evaluated on cultured liver cells (HepG2) and macrophages (J774 and P388D1) without observable toxicity. C12-resazurin viability assays were also used here to quantify cell viability on microglia. Cellular survival following incubation with increasing concentrations of SDIO is shown in Figure 3. Untreated cells (blank) served as the control. Fluorescent intensities, which reflected fractional survival of treated cells, were normalized against the signal intensities from the untreated cells. The average viability exceeds 95% after 4 or 24 h incubation with nanoparticles. An unpaired, two-tailed t-test was performed to compare treated cells against the control within each time point. There was no significant difference () between the untreated cells and those incubated with SDIO at concentrations up to 5 mM, a concentration range relevant for in vivo MRI imaging.

Figure 3: Cell viability studies with C12-resazurin assay. BV2 cells were incubated for 4 and 24 h with different iron concentrations of SDIO. Fluorescent intensities reflecting fractional survival were normalized against the signal from the untreated cells. All error bars present standard error of the mean (SEM) ().
3.3. High Cellular Uptake of SDIO by Microglia

In our previous study with murine macrophages, sulfation of DIO facilitated SR-A targeting and enhanced microglial uptake. There was also a trend that uptake efficiency increased with higher sulfation levels on the nanoparticles. In this work, we identified the same trends when assessing the uptake of SDIO and DIO by microglia (BV2 cells) at 37°C. The T2 values of the cell lysates of microglia incubated with SDIO or DIO for 2 h are shown in Figure 4. There was significantly less uptake of the untargeted DIO (black bar) at 25, 50, and 100 µM. With sulfation on the nanoparticles, the T2 decreased greatly for cells incubated with SDIO. T-test statistical calculations confirmed significant differences between the untreated cells and those incubated with SDIO (), while the difference between untreated cells and cells treated with DIO was not significant (), indicating that there was very little nonspecific uptake of nanoparticles by microglia. As the transverse relaxivity of SDIO (72.8 mM−1·s−1) was smaller than that of DIO (103.3 mM−1·s−1) due to the surface modification, there is actually an additional 1.4-fold increase in particle uptake efficiency for SDIO compared to that of DIO. This indicates that the surface sulfation significantly improved targeting to microglia and far exceeded the compensation for the decrease in relaxivities. This expected result suggested that more SDIO nanoparticles could accumulate in activated microglia when intravenously injected compared to injection of the same amount of the untargeted DIO.

Figure 4: Specific uptake of SDIO nanoparticles by BV2 cells compared to nonsulfated analog DIO. Accumulation of iron oxide in cells reduced the transverse relaxation times of cell lysates. All error bars present SEM ().
3.4. In Vivo Visualization of Inflammation and Histological Confirmation

A mouse model of brain inflammation generated by unilateral intracerebral injection of TNF-α was previously reported in the literature [28]. TNF-α is a key regulator of the inflammatory response with its strong effect on vascular endothelium and endothelial leukocyte interactions [32]. In response to TNF-α, endothelial cells promote inflammation by displaying adhesion molecules for leukocyte recruitment. Here, to verify that intravenous administration of SDIO specifically detects neuroinflammation, we imaged the following groups: (1) TNF-α-only group (), (2) IV-SDIO-only group (), (3) TNF-α + IV-SDIO group (), and (4) TNF-α + IV-DIO group ().

As shown in Figure 5(a) (row 1), MR images of animals from the TNF-α-only group did not show much signal change 22 hours after TNF-α inoculation (before IV). The needle track at this time point was barely observable. MRI recorded 28 hours after surgery (4 h after IV) revealed only slightly enhanced negative contrast along the needle track (red arrows in Figure 5(a), row 1). These changes became more visible 24 and 48 hours after IV. This is probably due to increased inflammation and microhemorrhages with time. On the histological image, a small cavitation representing tissue loss was also detected. Anti-Iba-1 antibody staining confirmed the presence of activated microglia along the site of TNF-α inoculation (Figures 5(b) and 5(c)). A slight Perls’ positive staining was also detected in the vicinity of the lesion, likely due to microhemorrhages along the needle track (Figures 5(b) and 5(c)).

Figure 5: Representative -weighted MRI and histological staining of mouse brains from different imaging groups. (a) -weighted MR images in each row represent MRI scans at different time points from the same animal in that group. The second row is an animal that did not receive intracerebral injection, only intravenous SDIO injection. The other three rows are animals that underwent TNF-α intracerebral injections. From left to right, column 1 represents images after TNF-α injection, but before IV injection of contrast agent, the rest of the columns of MRI represent time points after intravenous injection of stated contrast agent (except for row 1, these animals were not injected with contrast agents). Red arrows denote the needle tracks and regions highlighted by contrast agents. (b–i) Histological evaluation of the same animals as shown in (a): (b, c) TNF-α only; (d, e) IV-SDIO only; (f, g) TNF-α + IV-SDIO; (h, i) TNF-α + IV-DIO. Blue arrows in (b), (f), and (h) denote small cavities in the brain that were observed. Images (c), (e), (g), and (i) show magnification of Iba-1 and iron staining of selected areas (red square) from images (b), (d), (f), and (h). Activated microglia at inflammation sites were stained brown by Iba-1 antibody, while iron oxide nanoparticles accumulated in the vicinity region were stained blue by Perls’ Prussian blue. Scale bars represent 200 µm.

MR images of the IV-SDIO-only control group (Figure 5(a), row 2) exhibited no accumulation of contrast in the intact brain as expected, suggesting that in the absence of cerebral inflammation and blood-brain barrier (BBB) disruption, the nanoparticles do not cross the BBB to accumulate in the brain. The histological staining (Figures 5(d) and 5(e)) did not demonstrate notable iron staining.

We compared -weighted contrast of the glial scar produced by intracerebral TNF-α treatment groups and in groups that then received intravenous administration of either SDIO or DIO (Figure 5(a), rows 3 and 4, resp.). Twenty-two hours after unilateral (left) TNF-α inoculation, prior to contrast injection, no obvious signal changes could be detected at the site of the inoculation in any group (Figure 5(a), before IV). Four hours after IV injection of SDIO, the MR images displayed an area with strong negative contrast in the left side of the brain where TNF-α was injected (Figure 5(a), row 3). The region of signal hypointensity was larger and through a greater brain depth in the SDIO group (row 3) than the TNF-α group that received DIO (row 4). There was no signal alteration in the control contralateral cortical hemisphere consistent with preferential uptake of the SDIO particles at the sites of focal inflammation. Quantitative analysis showed that CNR (calculated as the difference in signal intensity between the injured site and the control region in the contralateral side of the brain scaled to image background noise) reached 17 at 4 h post-IV injection scan (Figure 6). The absence of detectable signal changes in the MRI scan immediately after surgery and before SDIO injection (Figure 5(a)) indicates that the subsequent hypointensities following SDIO in the treated left hemisphere were a consequence of uptake of the iron oxide nanoparticles. Pathology did not demonstrate evidence of acute hemorrhage. The negative contrast was strongest at 24 h post-IV injection (Figure 5(a), row 3) and the CNR reached 49 (14-fold increase from the pre-IV scan) at this time point (Figure 6), which suggests higher accumulation of SDIO at the inflammatory site. The negative contrast then weakened slightly by 48 h post-IV injection and the CNR decreased to 26 (Figures 5(a) and 6).

Figure 6: Average CNR of SDIO and DIO from MR images at different time points. All four animals from the experimental groups were calculated. , . All error bars present SEM ().

For the TNF-α + IV-SDIO group, histological evaluations (Figures 5(f) and 5(g)) showed a small cavitation (blue arrow), a consequence of local cellular death following direct TNF-α instillation, representing a loss of dead or dying brain tissue during histological processing. TNF-α induced cavities were nonhemorrhagic and narrower in caliber than the corresponding broad hypodensities visualized 24 and 48 h. Anti-Iba-1 antibody staining confirmed the presence of activated microglia at the site of TNF-α inoculation. We also found blue staining throughout the inflammatory lesion, indicating iron oxide nanoparticles accumulated in the injured hemisphere. The colocalization of the immunostaining and iron staining showed that iron oxide accumulated in microglia at the inflammatory sites and there was a strong correlation with the extent of iron staining to the contrast enhancement on the -weighted images.

Unlike the TNF-α + IV-SDIO group, the TNF-α + IV-DIO group did not present pronounced signal change after TNF-α inoculation (Figure 5(a) row 4 and Figure 6). Similar to the TNF-α-only group, the TNF-α + IV-DIO group displayed slightly enhanced negative contrast along the needle track but with very weak contrast compared to the TNF-α + IV-SDIO group, and the CNR in the TNF-α + IV-DIO group was under 10 for all time points. A significant difference between the TNF-α + IV-SDIO and TNF-α + IV-DIO conditions was reached 24 and 48 hours after the IV injection of the contrast agents (Figure 6, unpaired t-test ). As the group size was small (), we also performed Mann–Whitney U test to compare the CRN of IV-SDIO and IV-DIO at different time points. Mann–Whitney U is a nonparametric test that does not require the assumption of normal distribution and suits better for small sample size. U at 4 h, 24 h, and 48 h after IV was 4, 1, and 0, respectively. Similar to the t-test, a significant difference () was also found between the TNF-α + IV-SDIO and the TNF-α + IV-DIO groups at 48 h post-IV injection. These results suggested inefficient uptake of DIO by microglia in the inflamed region. Histological results from the TNF-α + IV-DIO group also showed a small cavitation and activated microglia at the site of TNF-α inoculation (Figures 5(f) and 5(g)).

These results indicate that, with the same injected iron dose, SDIO accumulated preferentially compared to DIO particles at the sites of TNF-α inoculation, that is, neuroinflammation. Thus, sulfated nanoparticles are excellent, targeted contrast agents that enhance signal from microglia in vivo compared to conventional dextran-coated iron oxide. The result parallels that from the in vitro uptake studies (Section 3.3) where SDIO nanoparticles were more efficiently and avidly taken up by BV2 cells. The marked specificity of SDIO uptake by microglia is in contrast to SDIO uptake by macrophages that we have previously reported: microglia seem to show negligible uptake of the nontargeted DIO particles while macrophages showed reduced but measurable in vivo uptake of DIO [27]. The labeling of activated microglia by SDIO, thus, is comparatively much more selective than that of activated macrophages.

4. Discussion

MRI has shown great clinical utility for its high-resolution, noninvasive imaging of the brain without using ionizing radiation. Visualizing information about inflammatory processes such as activation of microglia can contribute to the understanding of the progression of neurotoxicity and cognitive impairment, facilitating development of improved treatments for neurodegenerative diseases. Previous studies have attempted to use endogenous iron deposits in activated microglia to generate contrast on MR images [33]. However, the poor signal from endogenous iron-labeled microglia limits the approach for a general assessment in the brain. Thus, various imaging agents have been under development to detect focal accumulations of activated microglia by MRI.

Fleig and colleagues previously reported labeling activated microglia with untargeted, ultrasmall superparamagnetic iron oxide (USPIO) nanoparticles in culture and in a rat glioma model [34]. Confocal microscopy of isolated brain sections showed localization of USPIO in microglia and macrophages. Although there is inflammatory activity that can sequester nontargeted agents, microglial uptake of USPIO was not efficient and transport was presumably through the enhanced permeability and retention effect. Previous MRI studies in animal models have used dextran-coated iron oxide doses up to 30 mg/kg body mass, 60 times the normal human dose (0.56 mg of iron/kg body weight [35]). This suggested that improved targeting and sequestration by microglia could reduce dose requirements.

Through SR-A, microglia interact with many components of cerebral inflammatory injury, such as oxidized low-density lipoprotein, amyloid fibrils, and apoptotic neurons [36, 37]. SR-A receptors have broad ligand specificity for a diverse array of polyanionic macromolecules, such as maleylated bovine serum albumin (mal-BSA), oxidized LDL, malondialdehyde-modified LDL, and polyinosinic acid [3841]. The SR-A-targeted probes that we have developed indicate a significant improvement in the targeting and uptake of sulfated dextran-coated iron nanoparticles.

Here, we provide a first proof that SDIO labels in vivo microglia activated by intracerebral administration of TNF-α. In normal brain where the BBB is intact, entry of nanomaterials is very restricted, as passive diffusion of substances across the BBB endothelial cells is normally limited to small, lipophilic molecules less than 500 Da [42]. In this study, we wanted to focus on the targeting of microglia by SDIO and designed a TNF-α-based protocol inducing microglial activation associated with BBB disruption. SDIO but not the untargeted DIO particles showed significant labeling ability. This supports that labeling by SDIO is not simply due to microglial sequestration of material that passively diffused across the open BBB. First applications of SDIO without further modification of the contrast agents could thus target pathologies such as traumatic injuries, multiple sclerosis, or brain tumors in which the BBB is temporarily opened or chronically damaged [43].

Although it has long been known that BBB compromise commonly occurs in inflammation, infection, and all neurodegenerative disorders [44, 45], the damage to the BBB can be much milder than the trauma generated by intracerebral injections. Thus, SDIO may require modifications to penetrate the brain in applications where the BBB is not, or only slightly, opened. All nanoparticle-based agents face the challenge of penetrating the blood-brain barrier, and a number of methods described in the literature to overcome the BBB, such as the opening of tight junctions using osmotic pressure or ultrasound disruption, can effectively generate pores in the BBB that enable the entry of imaging agents or therapeutics to the brain [46, 47]. Future studies will need to modify SDIO and evaluate the improved formulation in models with milder BBB disruptions.

Transport of materials across the BBB is an active area of study by others, and previous works have demonstrated that coating nanoparticles with ligands (such as insulin or transferrin) or surfactants (such as polysorbate 80) could improve the passage through blood-brain barrier after systemic administration [4850]. Surfactants can either directly disrupt the tight junctions or allow NPs absorbing to plasma protein, such as apolipoprotein E, to cross the BBB through endothelial cells by receptor-mediated transcytosis or endocytosis [51]. It has also been shown that magnetic heating (hyperthermia) of magnetic nanoparticles by a low radiofrequency field can increase BBB permeability without perturbing other brain cells [52]. This transient disruption of BBB is local and entirely reversible and could be potentially achieved by our SDIO nanoparticles. Methods that can keep SDIO in circulation longer and mediate transport across the BBB will greatly increase efficiency for detection of microglia in the brain and are topics for our future studies.

Future studies may also focus on the use of SDIO for other imaging methods. It is interesting to note that SDIO is conjugated with a macrocyclic chelator, which captures radionuclides including 64Cu, so that it could potentially be employed as a PET or PET/MRI multimodal agent [53]. PET is a very sensitive method, and SDIO-based contrast agents could be beneficial where low numbers of activated microglia are to be visualized or in diseases in which the crossing of BBB by SDIO is low.

5. Conclusions

We demonstrated the ability of SDIO targeting SR-A to image microglia actively involved in brain inflammation. The functionalized iron oxide nanoparticles were proven to be nontoxic and were efficiently internalized by activated microglia in vitro and in vivo. In a mouse model of brain inflammation, SDIO rendered much better in vivo contrast enhancement compared to the nonspecific, nonsulfated analog. These results support that SDIO is a promising MRI contrast agent, with potential multimodal function, to image activated microglia in inflammation and assess disease progression.

Data Availability

Data of the study are available upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest regarding the publication of this article.

Acknowledgments

The authors wish to acknowledge the National Institutes of Health (EB008576-01 and EB000993), the NMR award of the University of California, Davis, and the ERASMUS MUNDUS program of the European Commission for support of this work. They also thank Dr. J. Walton for his help on MRI studies.

References

  1. W. J. Streit, R. E. Mrak, and W. S. T. Griffin, “Microglia and neuroinflammation: a pathological perspective,” Journal of Neuroinflammation, vol. 1, no. 1, p. 14, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. L. J. Chew, A. Takanohashi, and M. Bell, “Microglia and inflammation: impact on developmental brain injuries,” Mental Retardation and Developmental Disabilities Research Reviews, vol. 12, no. 2, pp. 105–112, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Giulian, “Microglia and the immune pathology of Alzheimer disease,” American Journal of Human Genetics, vol. 65, no. 1, pp. 13–18, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. M. E. Smith, “Phagocytic properties of microglia in vitro: implications for a role in multiple sclerosis and EAE,” Microscopy Research and Technique, vol. 54, no. 2, pp. 81–94, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Town, J. Tan, R. A. Flavell, and M. Mullan, “T-cells in Alzheimer’s disease,” NeuroMolecular Medicine, vol. 7, no. 3, pp. 255–264, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. H. L. Weiner and D. Frenkel, “Immunology and immunotherapy of Alzheimer’s disease,” Nature Reviews Immunology, vol. 6, no. 5, p. 404, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. V. H. Perry and C. Holmes, “Microglial priming in neurodegenerative disease,” Nature Reviews Neurology, vol. 10, no. 4, pp. 217–224, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. H. González, D. Elgueta, A. Montoya, and R. Pacheco, “Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases,” Journal of Neuroimmunology, vol. 274, no. 1, pp. 1–13, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. C. A. Wiley, B. J. Lopresti, S. Venneti et al., “Carbon 11–labeled Pittsburgh compound b and carbon 11–labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer Disease,” Archives of Neurology, vol. 66, no. 1, pp. 60–67, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. A. M. Dickens, S. Vainio, P. Marjamäki et al., “Detection of microglial activation in an acute model of neuroinflammation using PET and radiotracers 11C-(R)-PK11195 and 18F-GE-180,” Journal of Nuclear Medicine, vol. 55, no. 3, pp. 466–472, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. W. C. Kreisl, M. Fujita, Y. Fujimura et al., “Comparison of [11C]-(R)-PK 11195 and [11C] PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: implications for positron emission tomographic imaging of this inflammation biomarker,” NeuroImage, vol. 49, no. 4, pp. 2924–2932, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. P. S. Bloomfield, S. Selvaraj, M. Veronese et al., “Microglial activity in people at ultra high risk of psychosis and in schizophrenia: an [11C] PBR28 PET brain imaging study,” American Journal of Psychiatry, vol. 173, no. 1, pp. 44–52, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. C. M. Sandiego, J.-D. Gallezot, B. Pittman et al., “Imaging robust microglial activation after lipopolysaccharide administration in humans with PET,” Proceedings of the National Academy of Sciences, vol. 112, no. 40, pp. 12468–12473, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. S. I. Savitz and C. S. Cox, “Concise review: cell therapies for stroke and traumatic brain injury: targeting microglia,” Stem Cells, vol. 34, no. 3, pp. 537–542, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. D. R. Owen, A. J. Yeo, R. N. Gunn et al., “An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28,” Journal of Cerebral Blood Flow and Metabolism, vol. 32, no. 1, pp. 1–5, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Tronel, B. Largeau, M. J. Santiago Ribeiro, D. Guilloteau, A.-C. Dupont, and N. Arlicot, “Molecular targets for PET imaging of activated microglia: the current situation and future expectations,” International Journal of Molecular Sciences, vol. 18, no. 4, p. 802, 2017. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Toyama, K. Hatano, H. Suzuki et al., “In vivo imaging of microglial activation using a peripheral benzodiazepine receptor ligand: [11C] PK-11195 and animal PET following ethanol injury in rat striatum,” Annals of Nuclear Medicine, vol. 22, no. 5, pp. 417–424, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. J. Husemann, J. D. Loike, R. Anankov, M. Febbraio, and S. C. Silverstein, “Scavenger receptors in neurobiology and neuropathology: their role on microglia and other cells of the nervous system,” Glia, vol. 40, no. 2, pp. 195–205, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. G. V. Limmon, M. Arredouani, K. L. McCann, R. A. C. Minor, L. Kobzik, and F. Imani, “Scavenger receptor class-A is a novel cell surface receptor for double-stranded RNA,” FASEB Journal, vol. 22, no. 1, pp. 159–167, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Santiago-Garcı́a, T. Kodama, and R. E. Pitas, “The class A scavenger receptor binds to proteoglycans and mediates adhesion of macrophages to the extracellular matrix,” Journal of Biological Chemistry, vol. 278, no. 9, pp. 6942–6946, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Abraham, N. Singh, A. Mukhopadhyay, S. K. Basu, V. Bal, and S. Rath, “Modulation of immunogenicity and antigenicity of proteins by maleylation to target scavenger receptors on macrophages,” Journal of Immunology, vol. 154, no. 1, pp. 1–8, 1995. View at Google Scholar
  22. L. G. Fong and D. Le, “The processing of ligands by the class A scavenger receptor is dependent on signal information located in the cytoplasmic domain,” Journal of Biological Chemistry, vol. 274, no. 51, pp. 36808–36816, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Józefowski, “The role of the class A scavenger receptors, SR-A and MARCO, in the immune system. Part 1. The structure of receptors, their ligand binding repertoires and ability to initiate intracellular signaling,” Postepy Higieny I Medycyny Doswiadczalnej, vol. 66, pp. 104–119, 2012. View at Google Scholar
  24. N. Platt, R. Haworth, L. Darley, and S. Gordon, “The many roles of the class A macrophage scavenger receptor,” International Review of Cytology, vol. 212, pp. 1–42, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. B. R. Jarrett, M. Frendo, J. Vogan, and A. Y. Louie, “Size-controlled synthesis of dextran sulfate coated iron oxide nanoparticles for magnetic resonance imaging,” Nanotechnology, vol. 18, no. 3, p. 035603, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. B. R. Jarrett, B. R. Gustafsson, D. L. Kukis, and A. Y. Louie, “Synthesis of 64Cu-labeled magnetic nanoparticles for multimodal imaging,” Bioconjugate Chemistry, vol. 19, no. 7, pp. 1496–1504, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. C. Tu, T. S. Ng, H. K. Sohi et al., “Receptor-targeted iron oxide nanoparticles for molecular MR imaging of inflamed atherosclerotic plaques,” Biomaterials, vol. 32, no. 29, pp. 7209–7216, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Montagne, M. Gauberti, R. Macrez et al., “Ultra-sensitive molecular MRI of cerebrovascular cell activation enables early detection of chronic central nervous system disorders,” NeuroImage, vol. 63, no. 2, pp. 760–770, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. J. L. Goldstein, Y. K. Ho, S. K. Basu, and M. S. Brown, “Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition,” Proceedings of the National Academy of Sciences, vol. 76, no. 1, pp. 333–337, 1979. View at Publisher · View at Google Scholar
  30. T. Tang, C. Tu, S. Y. Chow, K. H. Leung, S. Du, and A. Y. Louie, “Quantitative assessment of binding affinities for nanoparticles targeted to the vulnerable plaque,” Bioconjugate Chemistry, vol. 26, no. 6, pp. 1086–1094, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. C. A. Schneider, W. S. Rasband, and K. W. Eliceiri, “NIH Image to ImageJ: 25 years of image analysis,” Nature Methods, vol. 9, no. 7, p. 671, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Bradley, “TNF-mediated inflammatory disease,” Journal of Pathology, vol. 214, no. 2, pp. 149–160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. M. M. Zeineh, Y. Chen, H. H. Kitzler, R. Hammond, H. Vogel, and B. K. Rutt, “Activated iron-containing microglia in the human hippocampus identified by magnetic resonance imaging in Alzheimer disease,” Neurobiology of Aging, vol. 36, no. 9, pp. 2483–2500, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Fleige, C. Nolte, M. Synowitz, F. Seeberger, H. Kettenmann, and C. Zimmer, “Magnetic labeling of activated microglia in experimental gliomas,” Neoplasia, vol. 3, no. 6, pp. 489–499, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. V. M. Runge, “Safety of approved MR contrast media for intravenous injection,” Journal of Magnetic Resonance Imaging, vol. 12, no. 2, pp. 205–213, 2000. View at Publisher · View at Google Scholar
  36. Y. Xu, L. Qian, G. Zong et al., “Class A scavenger receptor promotes cerebral ischemic injury by pivoting microglia/macrophage polarization,” Neuroscience, vol. 218, pp. 35–48, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Hooper, V. A. Fry, I. G. Sevastou, and J. M. Pocock, “Scavenger receptor control of chromogranin A-induced microglial stress and neurotoxic cascades,” FEBS Letters, vol. 583, no. 21, pp. 3461–3466, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Horiuchi, Y. Sakamoto, and M. Sakai, “Scavenger receptors for oxidized and glycated proteins,” Amino Acids, vol. 25, no. 3-4, pp. 283–292, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Krieger, “Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP),” Annual Review of Biochemistry, vol. 63, no. 1, pp. 601–637, 1994. View at Publisher · View at Google Scholar
  40. P. J. Gough and S. Gordon, “The role of scavenger receptors in the innate immune system,” Microbes and Infection, vol. 2, no. 3, pp. 305–311, 2000. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Platt and S. Gordon, “Is the class A macrophage scavenger receptor (SR-A) multifunctional?—The mouse’s tale,” Journal of Clinical Investigation, vol. 108, no. 5, pp. 649–654, 2001. View at Publisher · View at Google Scholar
  42. S. Wohlfart, S. Gelperina, and J. Kreuter, “Transport of drugs across the blood–brain barrier by nanoparticles,” Journal of Controlled Release, vol. 161, no. 2, pp. 264–273, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Price, C. Wilson, and G. Grant, Blood–Brain Barrier Pathophysiology following Traumatic Brain Injury, U.S. National Library of Medicine, Bethesda MD, USA, 2016.
  44. B. Obermeier, R. Daneman, and R. M. Ransohoff, “Development, maintenance and disruption of the blood-brain barrier,” Nature Medicine, vol. 19, no. 12, p. 1584, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. M. A. Erickson, K. Dohi, and W. A. Banks, “Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier,” Neuroimmunomodulation, vol. 19, no. 2, pp. 121–130, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. T.-T. Zhang, W. Li, G. Meng, P. Wang, and W. Liao, “Strategies for transporting nanoparticles across the blood–brain barrier,” Biomaterials Science, vol. 4, no. 2, pp. 219–229, 2016. View at Publisher · View at Google Scholar · View at Scopus
  47. M. D. Santin, T. Debeir, S. L. Bridal, T. Rooney, and M. Dhenain, “Fast in vivo imaging of amyloid plaques using μ-MRI Gd-staining combined with ultrasound-induced blood–brain barrier opening,” NeuroImage, vol. 79, pp. 288–294, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. D. T. Wiley, P. Webster, A. Gale, and M. E. Davis, “Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor,” Proceedings of the National Academy of Sciences, vol. 110, no. 21, pp. 8662–8667, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Kreuter, V. Petrov, D. Kharkevich, and R. Alyautdin, “Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood–brain barrier using surfactant-coated nanoparticles,” Journal of Controlled Release, vol. 49, no. 1, pp. 81–87, 1997. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Petri, A. Bootz, A. Khalansky et al., “Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly (butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants,” Journal of Controlled Release, vol. 117, no. 1, pp. 51–58, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. C. Saraiva, C. Praça, R. Ferreira, T. Santos, L. Ferreira, and L. Bernardino, “Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases,” Journal of Controlled Release, vol. 235, pp. 34–47, 2016. View at Publisher · View at Google Scholar · View at Scopus
  52. S. N. Tabatabaei, H. Girouard, A.-S. Carret, and S. Martel, “Remote control of the permeability of the blood–brain barrier by magnetic heating of nanoparticles: a proof of concept for brain drug delivery,” Journal of Controlled Release, vol. 206, pp. 49–57, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. B. R. Jarrett, C. Correa, K. L. Ma, and A. Y. Louie, “In vivo mapping of vascular inflammation using multimodal imaging,” PLoS One, vol. 5, no. 10, Article ID e13254, 2010. View at Publisher · View at Google Scholar · View at Scopus